Stay updated on GS-1811 Study With Zimberelimab in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the GS-1811 Study With Zimberelimab in Advanced Solid Tumors Clinical Trial page.

Latest updates to the GS-1811 Study With Zimberelimab in Advanced Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe clinical trial record for denikitug, alone or with zimberelimab, is displayed with study design, participant eligibility, recruitment locations, and outcome measures. The study is listed as active but no longer recruiting.SummaryDifference62%

- Check11 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedAn NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the study-record page, and the site revision changes from v3.7.1 to v3.7.2. The study record itself remains inaccessible behind a 403 Forbidden error.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check46 days agoChange DetectedAn error state (403 Forbidden) is now displayed on the page, replacing the study details and navigation with a standard error screen. This indicates access to the study record is denied.SummaryDifference19%

- Check60 days agoChange DetectedThe label 'Find Contact Information' was standardized to 'Find contact information'. The UI revision tag changed from 'Revision: v3.6.6' to 'Revision: v3.7.0'.SummaryDifference0.1%

Stay in the know with updates to GS-1811 Study With Zimberelimab in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS-1811 Study With Zimberelimab in Advanced Solid Tumors Clinical Trial page.